Journal
Discover Oncology
Discover Oncology is an open access journal publishing content that interfaces at all levels of cancer research.
Despite significant advancements in cancer drug development and therapy, breast cancer remains the second leading cause of death among women worldwide. The heterogeneity of this disease continues to be a major concern. However, advances in molecular biology and immunology have enabled the introduction of targeted therapies for various forms of breast cancer.
Targeted therapy represents a significant shift in cancer treatment, focusing on the specific molecular and genetic profiles of tumors. Personalized medicine, which is based on the principle that there is no “one size fits all” treatment, has seen a substantial increase in the development of targeted therapies. In fact, personalized medicines accounted for one-third of new U.S. Food and Drug Administration (FDA) drug approvals for the fourth consecutive year in 2023, underscoring this trend.
The future of cancer treatment is increasingly focused on understanding a patient’s genetic profile and incorporating the immunological landscape of tumor cells and the tumor microenvironment to achieve therapeutic success through targeted therapies.
Submit your manuscript to this collection through the participating journal.
-
Zaheed Husain
Professor, the Molecular Cancer Diagnostic and Medical Services Lab at Praava Health, Bangladesh. His research focused on immune tolerance in cancer, particularly Tregs and MDSCs. Over 15 years, he developed protocols for gene expression analysis, identified apoptosis pathways in B cells, and studied NK cell receptors. Currently, as Senior Director at Praava Health, Bangladesh, he leads the Molecular Cancer Diagnostics Lab. Dr. Husain holds a PhD in molecular biology and biochemistry and has multiple publications and patents.
